Clinical OMICS

MAY-JUN 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 27 of 50

26 Clinical OMICs May/June 2019 D avid Bentley trained in medical genetics at Guy's Hospital in London before spending 12 years at the Sanger Centre (now the Wellcome Trust Sanger Insti- tute). There, as Head of Human Genetics and working with director Sir John Sulston and colleagues, he helped set up the British arm of the Human Genome Project. In 2005, Bentley joined a British next-gen sequencing start-up called Solexa (having been an advisor since launch in 1998). Solexa had just sequenced the virus PhiX174 genome—the same genome Fred Sanger sequenced (also at Cambridge) 20 years earlier. In 2007, Illumina acquired Solexa, and has been reaping the rewards ever since. As VP and chief scientist, Bentley has steered the applications of Illumina's sequencing platform in many directions in precision medicine. Here, he talks to Clin- ical OMICs chief editor Chris Anderson about the com- pany's latest work with the 100,000 Genomes Project, Genomics England, and the U.K. National Health Ser- vice, and more broadly about the role of genome sequence data in the precision medicine landscape. Are we reaching the end point with the 100,000 Genomes Project that you envisioned when you started with the Sanger Institute? Bentley: For me it all started really at Guy's Hospital, London. That's when we had people come in with monogenic conditions, we were finding mutations, and offering some form of diagno- sis or genetic counseling based on DNA sequence information. As you say, we've come full circle through the Human Genome David Bently CSO, Illumina IN CONVERSATION

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2019